[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[2] Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma[J]. Genes Dis. 2020,7(3):308-319.
[3] Rooks J B, Ory H W, Ishak K G, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use[J]. JAMA,1979,242(7):644-648.
[4] Wang X, Zhang X. Hepatocellular adenoma: where are we now?[J]. World J Gastroenterol, 2022, 28(14):1384-1393.
[5] Putra J, Ferrell L D, Gouw A S H, et al. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon[J]. Mod Pathol, 2020, 33(4):665-675.
[6] Nault J C, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation[J]. Gastroenterology, 2017,152(4):880-894.e6.
[7] Calderaro J, Labrune P, Morcrette G, et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I[J]. J Hepatol. 2013,58(2):350-357.
[8] Frenette C, Mendiratta-lala M, Salgia R, et al. ACG clinical guideline: focal liver lesions[J]. Am J Gastroenterol, 2024,119(7):1235-1271.
[9] European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of benign liver tumours[J]. J Hepatol, 2016,65(2):386-398.
[10] Laurent A, Dokmak S, Nault J C, et al. European experience of 573 liver resections for hepatocellular adenoma: a cross-sectional study by the AFC-HCA-2013 study group[J]. HPB (Oxford),2016,18(9):748-755.
[11] Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma[J]. Gut,2011,60(1):85-89.
[12] Khanna M, Ramanathan S, Fasih N,et al. Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma[J]. Insights Imaging, 2015,6(3):347-362.
[13] Grazioli L, Bondioni M P, Haradome H, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis[J]. Radiology, 2012,262(2):520-529.
[14] Sciarra A, Schmidt S, Pellegrinelli A, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy[J]. Liver Int, 2019,39(1):158-167.
[15] Agarwal S, Fuentes-Orrego J M, Arnason T, et al. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI[J]. AJR Am J Roentgenol,2014,203(4):W408-W414.
[16] Reizine E, Ronot M, Ghosn M, et al. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked beta-catenin activation in hepatocellular adenoma[J]. Eur Radiol,2021,31(5):3417-3426.
[17] Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014,3(3-4):458-468.
[18] Kim S Y, AN J, Lim Y S, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J]. JAMA Oncol, 2017,3(4):456-463.
[19] Li X, Li C, Wang R, et al. Combined application of gadoxetic acid disodium-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) in the diagnosis of chronic liver disease-induced hepatocellular carcinoma: a meta-analysis[J]. PLoS One, 2015,10(12):e0144247.
[20] Wu J Y, Sun J X, Wu J Y, et al. Impact of bile duct tumor thrombus on the long-term surgical outcomes of hepatocellular carcinoma patients: a propensity score matching analysis[J]. Ann Surg Oncol, 2022,29(2):949-958.
[21] 中国医师协会肝癌专业委员会.肝细胞癌合并胆管癌栓多学科诊治中国专家共识(2020版)[J]. 肝癌电子杂志,2021,8(1):16-22.
[22] Chen Z H, Feng J K, Sun J X, et al. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis[J]. HPB (Oxford),2022,24(4):547-557.
[23] Huang Q, Lin K, Wang L, et al. Postoperative adjuvant transarterial chemoembolization improves short-term prognosis of hepatocellular carcinoma with bile duct tumor thrombus: a propensity-score matching study[J]. Cancer Manag Res,2020,12:9183-9195.
[24] Mei J, Tang Y H, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol,2021,11:618206.
[25] He M K, Liang R B, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol,2021,13:17588359211002720.
[26] Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH)[J]. J Clin Oncol, 2023,41(1):117-127.
[27] Zhu H D, Li H L, Huang M S, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)[J]. Signal Transduct Target Ther, 2023,8(1):58. |
